New Approval for Metastatic Breast Cancer: Alpelisib

Monday, July 22, 2019

This past May, the FDA approved the targeted therapy alpelisib (Piqray) to treat certain hormone receptor-positive, HER2-negative breast cancers in postmenopausal women and in men. Up to 40 percent of people with metastatic hormone receptor-positive, HER2-negative breast cancer could be eligible to get the treatment, which targets a mutation on the PIK3CA gene. During this webinar, our speaker Adam Brufsky, MD, PhD, discusses this new medicine and some of the side effects that come with it. 

Alpelisib is the first PI3K inhibitor approved for breast cancer. Learn more about the FDA approval.  

View Presentation

The listeners to this webinar had more questions than we had time to answer. Medical oncologist Adam Brufsky, MD, PhD, agreed to answer the remaining questions in writing.

See the Q+A

More In Hormone Receptor-Positive